Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

DG DISPATCH - ECCO: Anastrazole Shows Equal Efficacy To Tamoxifen In Advanced Breast Cancer By David Loshak Special to DG News VIENNA, AUSTRIA -- September 16, 1999 -- The new anti-cancer drug anastrazole could become the first choice for treating postmenopausal women with advanced breast cancer, instead of the current first-ling treatment, the drug tamoxifen. That was suggested at the 10th European Conference on Clinical Oncology (ECCO), in Vienna Austria, by a Canadian investigator, Professor Jean-Marc Nabholtz, from Montreal. Dr. Nabholtz reported that anastrazole was "at least as effective" as tamoxifen, or even better in some respects. Anastrazole is already licensed for use in advanced breast cancer, but only after tamoxifen has failed to work adequately. "Our data confirm that anastrazole can now be considered as an alternative to tamoxifen as a first-line treatment for postmenopausal women with advanced breast cancer," Prof. Nabholtz said. "A statistical comparison shows that it conferred significant improvement in time-to-progression of the cancer compared with tamoxifen," he added. "And it was as at least as well tolerated in most respects." Now that anastrazole has proved effective in advanced breast cancer, the largest ever breast cancer trial will test its efficacy in early breast cancer. The ATAC (Anastrazole, Tamoxifen, Alone or in Combination (ATAC) trial will compare it with tamoxifen alone and with a combination of the two. ATAC took only three years to sign up more than 9,000 women in 22 countries on five continents. When it was outlined at a conference session, a delegate said he was "dismayed" that none of these countries was in eastern Europe or (apart from South Africa) in Africa. It was well known, he pointed out, that patients who take part in clinical trials do better than those who do not. It was therefore "deeply regrettable" that people in these poorer regions were denied such a golden opportunity to get the best treatment. Dr. Joan Houghton, of the London Cancer Trials Centre, agreed it was unfortunate but explained that the unusual rapidity of recruitment into the trial had made it impossible to include patients from these countries. E-mail this page to a friend or colleague! To print, use this version